Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,700 shares, a decrease of 21.4% from the January 15th total of 9,800 shares. Based on an average daily volume of 19,200 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the company’s stock are short sold.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation bought a new stake in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned about 0.71% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Price Performance

Shares of XBIO stock opened at $4.17 on Friday. The firm has a fifty day moving average of $4.17 and a two-hundred day moving average of $4.00. The firm has a market cap of $6.42 million, a P/E ratio of -1.57 and a beta of 2.23. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. On average, sell-side analysts expect that Xenetic Biosciences will post -1.01 EPS for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.